Satellite Banner
Technology Networks Header
Tuesday, September 23, 2014
Technology Networks
 
Register | Sign in
Home Page
  News
Return

Catalent Announces Launch of Catalent Applied Drug Delivery Institute

Published: Thursday, October 25, 2012
Last Updated: Thursday, October 25, 2012
Bookmark and Share
Launch of Institute at the 2012 AAPS Annual Meeting and Exposition, Chicago, IL.


For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here


Scientific News
Gene Expression Patterns in Pancreatic CTCs Revealed
Distinct patterns of gene expression in several groups of CTCs were identified, including significant differences from the primary tumor that may contribute to the ability to generate metastases and prove to be targets for improved treatment of the deadly tumor.
Promise for Treatment of Pancreatic Cancer
Ultrasound microbubbles can improve tumor absorption of cancer drugs.
Novel Drug Targeting Leukemia Cells Enters Clinical Trial
Phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for CLL patients.
What Lies Behind the Death of Stem Cells
Researchers have identified key processes that control stem cell survival, providing insights that could improve their use in medicine.
Genetic Testing for Prostate Cancer
Genetic testing can identify men at six-fold increased risk of prostate cancer.
Redefining High Risk Patients With Stage II Colon Cancer
microRNA-21 identified as an independent prognostic biomarker.
Leukemia Subtype Becomes More Common With Age
Genomic Analysis of 1,725 patients reveals the prevalence of Ph-like ALL increases with age.
Ovarian Cancer Oncogene Found in "Junk DNA"
The study is published online in this week in Cancer Cell.
New Genetic Target for a Different Kind of Cancer Drug
Upstream of the proteins that cancer cells use to proliferate sits RBM4, a gene-splicing protein that is drastically reduced in human lung and breast cancer cells.
Combination microRNA Therapy Suppresses Non-Small-Cell Lung Cancer
Findings offer a promising therapeutic avenue for NSCLC.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv